Zacks Research Has Positive Forecast for EW FY2025 Earnings

Key Points

• Zacks Research has increased its FY2025 earnings estimate for Edwards Lifesciences from $2.42 to $2.48 per share, above the current consensus estimate of $2.45.
• Edwards Lifesciences reported earnings of $0.67 per share for Q2, surpassing analysts' expectations of $0.62, with total revenue of $1.53 billion.
• Multiple analysts have raised their price targets for Edwards Lifesciences, with Piper Sandler now setting a target of $90.00 while maintaining an "overweight" rating on the stock.

Edwards Lifesciences Corporation (NYSE:EW - Free Report) - Equities research analysts at Zacks Research increased their FY2025 EPS estimates for shares of Edwards Lifesciences in a report issued on Wednesday, August 13th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.48 per share for the year, up from their prior forecast of $2.42. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences' Q4 2025 earnings at $0.58 EPS and Q1 2027 earnings at $0.75 EPS.

A number of other research analysts have also recently commented on the company. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft increased their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Morgan Stanley raised their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Finally, Wall Street Zen raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Price Performance

EW traded up $0.08 during trading on Thursday, reaching $78.26. The stock had a trading volume of 2,620,544 shares, compared to its average volume of 4,877,332. The stock has a market cap of $45.95 billion, a PE ratio of 11.26, a PEG ratio of 3.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences has a one year low of $64.00 and a one year high of $83.00. The business has a 50-day moving average of $77.13 and a 200-day moving average of $74.41.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%. The firm's revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 earnings per share.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president owned 33,496 shares of the company's stock, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,134 shares of company stock valued at $1,311,745. 1.29% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Edwards Lifesciences by 1.2% during the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company's stock valued at $5,474,515,000 after purchasing an additional 798,801 shares in the last quarter. Geode Capital Management LLC raised its holdings in Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company's stock worth $990,074,000 after acquiring an additional 45,555 shares during the last quarter. Jennison Associates LLC raised its holdings in Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company's stock worth $912,788,000 after acquiring an additional 1,584,958 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company's stock worth $714,006,000 after acquiring an additional 4,805,819 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in Edwards Lifesciences by 7.6% in the 4th quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock worth $603,741,000 after acquiring an additional 575,699 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.